John D. Shaughnessy

Winthrop Rockefeller Foundation — United States

Medicine · Health Sciences

88h-index31.0kcitations483works4.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Multiple Myeloma Research and Treatments(338), Protein Degradation and Inhibitors(111), Peptidase Inhibition and Analysis(74), Ubiquitin and proteasome pathways(41), Glycosylation and Glycoproteins Research(37)

Publications482 total

Cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients: Clinical outcomes and risk factors
Blood·2025Open Access
Long-Term Follow-Up of Patients With Multiple Myeloma Treated on Earlier Total Therapy Protocols
JAMA Oncology·2025· 2 cited
Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple myeloma
Cancer Biomarkers·2025· 1 citedOpen Access
Cystatin M/E Ameliorates Multiple Myeloma-Induced Hyper Osteolytic Bone Resorption
Cancers·2025· 1 citedOpen Access
Prior exposure to belantamab mafodotin influences outcomes with idecabtagene vicleucel in patients with multiple myeloma
Blood Advances·2025· 4 citedOpen Access
Targeting caseinolytic mitochondrial matrix peptidase, a novel contributor to the pathobiology of high-risk multiple myeloma
Blood·2025· 5 cited
Single-cell analysis of neoplastic plasma cells identifies myeloma pathobiology mediators and potential targets
Cell Reports Medicine·2025· 3 citedOpen Access
Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma
Blood Advances·2024· 5 citedOpen Access
Identification of Risk Factors for Myeloma Progression in African American Patients
Blood·2024
The Low-Bone (LB) Subtype of Multiple Myeloma Exhibits an Inferior Outcome in African Americans
Blood·2024
Multi-Omics Reveal Immune Microenvironment Alterations in Multiple Myeloma and Its Precursor Stages
Blood·2024· 1 citedOpen Access
Single Nuclei Multiomic Profiling of Transcriptional and Chromatin Accessibility of Tumor Cells Underlines Extensive Cis-Regulatory Interaction during Multiple Myeloma Progression
Blood·2024Open Access
Minimal Residual Disease (MRD) Status and Its Impact on Clinical Outcome Is Highly Variable in Multiple Myeloma and Dependent on Molecular Subgroups Defined By Gene Expression Profiling (GEP)
Blood·2024Open Access
Prior Exposure to Belantamab Mafodotin Influences Outcomes with Idecabtagene Vicluecel in Patients with Multiple Myeloma
Blood·2024· 1 citedOpen Access
Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma: A Real-World Experience
Blood·2024
Of Seven Molecular Subtypes in MGUS the Low Bone Disease (LB) Subtype Exhibits Resistance to Multiple Myeloma Progression
Blood·2024Open Access
The Role of CST6 in Immunosuppression in the Multiple Myeloma Microenvironment
Blood·2024Open Access
Psychological Impact in Individuals with Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma
Clinical Hematology International·2024· 8 citedOpen Access
Cystatin M/E ameliorates bone resorption through increasing osteoclastic cell estrogen influx
2024Open Access
A Risk Stratification System in Myeloma Patients with Autologous Stem Cell Transplantation
Cancers·2024· 4 citedOpen Access
page 1 of 25Next →

Frequent Co-authors

Bart Barlogie(36), Fenghuang Zhan(20), Frits van Rhee(19), Guido Tricot(16), John Crowley(16), Elias Anaissie(14), Joshua Epstein(12), Maurizio Zangari(11), Mauricio Pineda‐Roman(10), Jeffrey R. Sawyer(9), Klaus Hollmig(9), Erming Tian(7), Yazan Alsayed(7), Ronald C. Walker(6), Yongsheng Huang(6), Ichiro Hanamura(6), Owen Stephens(6), Peter Stewart(5), W. Michael Kuehl(5), Susann Szmania(5)